Abstract:Background: The artificial liver support system (ALSS) is recognized as a bridge to liver transplantation (LT) in hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) patients; however, its impact on patient survival remains unknown. This study aimed to assess the effects of ALSS on survival in patients with HBV-ACLF. Methods: The clinical data of HBV-ACLF patients receiving standard medical treatment (SMT) plus ALSS (ALSS group, n = 507) or only SMT (SMT group, n = 417) were collected for survival assessment. The main endpoints were cumulative survival rates at days 21, 28 and 90. A case-control matched analysis was used to reduce bias between the ALSS and SMT groups. A propensity score matching (PSM) and inverse probability treatment weighting (IPTW) analysis were performed to confirm the survival effect of ALSS. Findings: In the entire cohort, the cumulative survival rates at days 21, 28 and 90 were significantly higher in patients who underwent ALSS treatment (73.3% vs. 59.6%, 69.2% vs. 56.6%, 56.5% vs. 49.1%, respectively, P <0.01) than in those who underwent SMT only. In the 276-pair case-control matched cohort, a significantly higher survival rate was also observed in the ALSS group than in the SMT group on days 21, 28 and 90 (72.5% vs. 60.3%, 68.3% vs. 57.4%, 55.9% vs. 48.5%, respectively, P <0.05), especially in patients with ACLF-1 and -2. By a multivariable-adjusted analysis, ALSS treatment was associated with a significantly lower risk of mortality, especially for ACLF-2 at days 21, 28 and 90 (HR: 0.587, 0.596 and 0.640, respectively). These findings were also confirmed through PSM and IPTW analysis (HR: 0.482/0.538 and 0.538/0.552 at day 21/28, respectively, P <0.01). Interpretation: Compared with SMT, ALSS treatment improved the short-term survival and was associated with a significantly lower risk of short-term mortality in patients with HBV-ACLF, especially ACLF-2. Funding Statement: The authors declared: None. Declaration of Interests: The authors stated: No conflict. Ethics Approval Statement: The study protocol was approved by the Clinical Research Ethics Committee of the First Affiliated Hospital, Zhejiang University School of Medicine (No. 2011-13). All patients were well informed, and written consent was obtained from the study subjects or the legal surrogates of patients before enrolment.

Artificial liver support system therapy in acute-on-chronic hepatitis B liver failure: Classification and regression tree analysis

Treatment of Hepatic Failure with Artificial Liver Support System.

Artificial Liver Support System Improves Short-Term Outcomes of Patients with HBV-Associated Acute-on-Chronic Liver Failure: A Propensity Score Analysis

Predictive values of three indexes on short-term prognosis in patients with liver failure treated by artificial liver support system

Efficacy of different therapeutic modalities for patients with acute-on-chronic liver failure induced by hepatitis B

A Prognostic Model for Hepatitis B Acute-on-chronic Liver Failure Patients Treated Using a Plasma Exchange-Centered Liver Support System.

Severe Hepatitis Treated with an Artificial Liver Support System

Artificial liver treatment improves survival in patients with hepatitis B virus‐related acute‐on‐chronic liver failure: A case‐control matched analysis

A non-bioartificial liver support system combined with transplantation in HBV-related acute-on-chronic liver failure

Effect of Artificial Liver Support System on Patients with Severe Viral Hepatitis: A Study of Four Hundred Cases

ARTIFICIAL LIVER TREATMENT IMPROVES SURVIVAL IN PATIENTS WITH ACUTE-ON-CHRONIC LIVER FAILURE: A PROPENSITY SCORE-MATCHED ANALYSIS

Circulating Proteomic Panels For Diagnosis And Risk Stratification Of Acute-On-Chronic Liver Failure In Patients With Viral Hepatitis B

Logistic Regression Model Can Reduce Unnecessary Artificial Liver Support in Hepatitis B Virus-Associated Acute-On-Chronic Liver Failure: Decision Curve Analysis

A prognostic score for patients with acute-on-chronic liver failure treated with plasma exchange-centered artificial liver support system

[Survival Analysis on Liver Failure Patients Treated with an Artificial Liver Support System].

Artificial Liver Support System Combined With Liver Transplantation In The Treatment Of Patients With Acute-On-Chronic Liver Failure

The curative effect of ALSS on 1-month mortality in AoCLF patients after 72 to 120 hours.

A Single-Center Experience of Non-Bioartificial Liver Support Systems among Chinese Patients with Liver Failure

Establishing a Metabolomic Model for the Prognosis of Hepatitis B Virus-Induced Acute-on-chronic Liver Failure Treated with Different Liver Support Systems

Effects of Artificial Liver Support System on Patients With Acute or Chronic Liver Failure

Plasma Exchange-Centered Artificial Liver Support System in Hepatitis B Virus-Related Acute-on-chronic Liver Failure: a Nationwide Prospective Multicenter Study in China.